×
Swiftmerge Acquisition EBIT 2022-2024 | IVCP
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Swiftmerge Acquisition ebit from 2022 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Swiftmerge Acquisition EBIT 2022-2024 | IVCP
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Swiftmerge Acquisition ebit from 2022 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$86.1B
Takeda Pharmaceutical (TAK)
$45.9B
Merck (MKGAF)
$21.6B
Astellas Pharma (ALPMY)
$21.1B
Sandoz Group AG (SDZNY)
$17.8B
United Therapeutics (UTHR)
$15.8B
Summit Therapeutics (SMMT)
$13.8B
Shionogi (SGIOY)
$12.6B
Neurocrine Biosciences (NBIX)
$11.5B
Catalent (CTLT)
$11B
Orion OYJ (ORINY)
$8B
Jazz Pharmaceuticals (JAZZ)
$6.8B
Ionis Pharmaceuticals (IONS)
$5.5B
Hikma Pharmaceuticals Plc (HKMPF)
$5.5B
Corcept Therapeutics (CORT)
$4.7B
Madrigal Pharmaceuticals (MDGL)
$4.5B
Crinetics Pharmaceuticals (CRNX)
$4.3B
Dyne Therapeutics (DYN)
$3.3B
PTC Therapeutics (PTCT)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Arrowhead Pharmaceuticals (ARWR)
$2.3B
Soleno Therapeutics (SLNO)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Harrow (HROW)
$1.8B
Recursion Pharmaceuticals (RXRX)
$1.7B
NewAmsterdam Pharma (NAMS)
$1.6B
Ardelyx (ARDX)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Ocular Therapeutix (OCUL)
$1.5B